University of Michigan

Mallinckrodt Medical, Inc.

Other

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Bayer Corporation

Steven L Kunkel

Robert M Strieter

Cory Hogaboam

Nicholas W Lukacs

Leon R Lyle

Vladislav A Dolgachev

Sem H Phan

Peter J Polverini

Raj K Puri

Elise Brownell

Claudia Jakubzick

Kenneth J Simpson

Cynthia L Bone-Larson

Lisa M Colletti

Cory M Hogaboam

Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

Antibody targeting stem cell factor

Stem cell factor inhibitor

Methods and compositions for the treatment of fibrosing diseases are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of CCL21 either alone or in combination with CCL19 will be effective in reducing the presence of fibrotic lesions and ameliorating the symptoms of fibrosing disorders.

Methods for treating pulmonary fibrosis

The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.

Chimeric molecule for the treatment of th2-like cytokine mediated disorders

Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.

Treatment of idiopathic pulmonary fibrosis using IP-10

Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.

Treatment of liver disease and injury with CXC chemokines

CXC chemokines as regulators of angiogenesis

This invention provides pharmaceutical compositions comprising anti-SCF antibodies for the reduction of eosinophila in the lungs of mammals. This invention also provides for methods of treating asthma and generating a murine model for asthma.

Method for treating asthma using SCF antibody

A method of imaging a target site in an animal's body in which a labelled chemokine is introduced into the animal's body and allowed to accumulate at a target site which includes corresponding receptor molecules. The accumulated, labelled chemokine material then is detected so as to image the target site of the body.

Radiolabeled neutrophil activating peptides for imaging

A composition suitable for administration to a warm-blooded animal comprising antisense MCP-1 peptide or oligonucleotide or a molecule capable of interacting with MCP-1 peptide or information for its synthesis which may or may not be labeled with a radionuclide by means of a chelate ligand capable of administration to an animal to produce reliable visual imaging of areas of potential restenosis or to produce therapeutic effects on areas of areas of potential restenosis.

Therapeutic treatment for inhibiting vascular restenosis

A method of imaging a target site in an animal's body in which a labelled CC chemokine or Monocyte Attractant Protein (MCP) material is introduced into the animal's body and allowed to accumulate at a target site which includes MCP receptor molecules. The accumulated, labelled MCP material is then detected so as to image the target site of the body.

Labelled monocyte chemoattractant protein material and medical uses

A method of imaging a target site in an animal's body in which a labelled CXC chemokine is introduced into the animal's body and allowed to accumulate at a target site which includes Interleukin-8 receptor molecules. The accumulated, labelled CXC chemokine is then detected so as to image the target site of the body.

Growing community of inventors

Ann Arbor, MI, United States of America

Steven L Kunkel